



Cervarix[®] [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] – Product Discontinuation

- [GlaxoSmithKline announced](#) the discontinuation of [Cervarix \[human papillomavirus bivalent \(types 16 and 18\) vaccine, recombinant\]](#) in the U.S. due to very low market demand.
 - The discontinuation is not due to product quality, safety, or efficacy concerns.
 - Existing stock of Cervarix can be distributed until the inventory is depleted. GSK's last ship date for Cervarix was August 31, 2016.
- Cervarix is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma *in situ*, and CIN grade 1.
- For further questions, contact the GSK Vaccine Service Center at **1-866-475-8222**.
- Other vaccines currently available for the prevention of HPV-related diseases include [Gardasil[®] \[HPV quadrivalent \(types 6, 11, 16 and 18\) vaccine, recombinant\]](#) and [Gardasil[®] 9 \[HPV 9-valent vaccine, recombinant\]](#). Refer to the respective drug labels for detailed indication information.

Action Plan

- The discontinuation of Cervarix will be presented at an upcoming Pharmacy & Therapeutics Committee meeting.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News[®] is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.